Public company snapshot, recent ticker-linked headlines, and a path into evidence-backed AI research.
Latest price
$109.93
-3.23%
Alpha Vantage · 11/6/2026
Adjusted daily closes · 252 observations · as of Nov 6, 2026
1 month
+12.3%
3 months
+1.8%
6 months
+32.1%
1 year
-9.9%
Year to date
-10.1%
52-week range
$81.49 – $127.45
Latest reported period: Sep 30, 2026
Market cap
$190.39B
P/E
40.5
P/B
3.7
P/S
3.9
Revenue
$48.23B
Net income
$4.7B
Diluted EPS
2.69
Gross margin
56.90%
Net margin
9.70%
Return on equity
9.00%
Total debt
$31.16B
Cash
$4.05B
Free cash flow
$6.76B
Reported quarterly values, newest first
| Period | Revenue | Net income | Gross margin | Net margin | Free cash flow |
|---|---|---|---|---|---|
| Sep 30, 2026 | $13.01B | $920M | 56.80% | 7.10% | $1.22B |
| Jun 30, 2026 | $12.59B | $928M | 57.70% | 7.40% | $1.99B |
| Mar 31, 2026 | $11.16B | $1.08B | 56.20% | 9.60% | $916M |
| Dec 31, 2025 | $11.46B | $1.78B | 57.00% | 15.50% | $2.63B |
| Sep 30, 2025 | $11.37B | $1.64B | 55.40% | 14.50% | $2.29B |
| Jun 30, 2025 | $11.14B | $1.78B | 56.40% | 16.00% | $1.55B |
| Mar 31, 2025 | $10.36B | $1.33B | 56.90% | 12.80% | $933M |
| Dec 31, 2024 | $10.97B | $9.23B | 55.00% | 84.10% | $2.15B |
Reported figures can reflect company reporting conventions, restatements, or sector-specific accounting. Verify against filings before relying on a valuation comparison.
In brief American Bitcoin, the Trump-family-backed, Hut 8-majority-owned miner, swung to roughly $126 million in net income in Q3, from a $57.2 million loss in Q2, with adjusted EBITDA of about $221 million. The turnaround leaned heavily on a $197 million gain on its digital assets as Bitcoin’s book value rose. Mining
Original sourceAbbott Laboratories (ABT) announced strong one-year VERITAS trial results for its Amulet 360 Left Atrial Appendage Occluder, showing high closure rates and low complications in non-valvular atrial fibrillation patients. This data strengthens Abbott's position in electrophysiology and structural heart devices, reinforcing its growth narrative despite broader nutritional and margin pressures. The company awaits FDA approval for Amulet 360 in the U.S. while the device is already CE marked in Europe.
Original source